Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ESRRG | P62508 | 1/20 | 0.37 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16391104 | 0.93 | CYP3A4 (0.52) | TDP1ALDH1A1CYP3A4MAPK1TSHR | |
| SCHEMBL10580706 | 0.90 | ALDH1A1 (0.64) | TDP1ALDH1A1CYP3A4MAPK1TSHR | |
| SCHEMBL13958424 | 0.89 | TDP1 (0.48) | TDP1ALDH1A1CYP3A4MAPK1TSHR | |
| SCHEMBL18562084 | 0.89 | KMT2A (0.37) | TDP1ALDH1A1CYP3A4MAPK1TSHR | |
| SCHEMBL7763544 | 0.89 | TDP1 (0.47) | TDP1ALDH1A1CYP3A4MAPK1TSHR | |
| SCHEMBL19980872 | 0.87 | ALDH1A1 (0.42) | TDP1ALDH1A1CYP3A4MAPK1TSHR | |
| SCHEMBL28639880 | 0.84 | TDP1 (0.43) | TDP1ALDH1A1CYP3A4MAPK1TSHR | |
| SCHEMBL19981027 | 0.83 | ALDH1A1 (0.39) | TDP1ALDH1A1CYP3A4MAPK1TSHR | |
| SCHEMBL20207410 | 0.83 | ALDH1A1 (0.37) | TDP1ALDH1A1CYP3A4MAPK1TSHR | |
| SCHEMBL3039281 | 0.82 | TDP1 (0.46) | TDP1ALDH1A1CYP3A4MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431592-B2 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| EP-2270008-B1 | 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors | NOVARTIS AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| US-20120207751-A1 | Imidazoquinolines as lipid kinase inhibitors | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2292617-B1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors | NOVARTIS AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| EP-1888578-B9 | 2-METHYL-2-[4-(3-METHYL-2-OXO-8-QUINOLIN-3-YL-2,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLINYL)-PHENYL]PROPIONITRILE AS LIPID KINASE INHIBITOR | NOVARTIS AG (CH) | 2012-04-25 | — | — | EP | disclosed |
| EP-1888578-B1 | 2-METHYL-2-[4-(3-METHYL-2-OXO-8-QUINOLIN-3-YL-2,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLINYL)-PHENYL]PROPIONITRILE AS LIPID KINASE INHIBITOR | NOVARTIS AG (CH) | 2011-11-30 | — | — | EP | disclosed |
| US-20110251202-A1 | 1,3-Dihydro-imidazo[4,5-c]quinolin-2-ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2011-10-13 | — | — | US | disclosed |
| US-7994170-B2 | 1,3-dihydro-imidazo[4,5-C]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-2292617-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors | Novartis AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| EP-2270008-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-7667039-B2 | 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1888578-A2 | IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006122806-A2 | 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | PDPK1, PI4KA, PIP4K2A | TDP1 3460/4885ALDH1A1 905/4885CYP3A4 1439/4885 |
| US-20120207751-A1 | Imidazoquinolines as lipid kinase inhibitors | PI4KA, PDPK1, PI4KB | TDP1 2975/4885ALDH1A1 2839/4885CYP3A4 1739/4885 |
| US-20110251202-A1 | 1,3-Dihydro-imidazo[4,5-c]quinolin-2-ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | TDP1 3460/4885ALDH1A1 905/4885CYP3A4 1439/4885 |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | TDP1 3460/4885ALDH1A1 905/4885CYP3A4 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.